This is randomized , open-label, multiple-dose, parallel study to compare the pharmacokinetics and to evaluate Drug-Drug Interaction of "CG-651" in healthy volunteers.

Total of 39 health volunteers will be randomized to receive either of Group A,B or C. (13 subjects each)

[Group A] Pregabalin+ Polmacoxib. [Group B] Polmacoxib [Group C] Pregabalin

Key Inclusion Criteria:

• Adequate Biochemistry, Urinalysis, Serology and so on.
• Subject who understand the objective, method of the study and the characteristics of investigational drug and expected adverse events and provide written informed consent prior to study participation.
• Negative pregnancy test (hCG) and agree to contraception during the trial.

Key Exclusion Criteria:

• History of hypersensitivity to investigational products.
• History of hypersensitivity or allergic reaction to sulfonamide.
• Patients with a history of asthma, acute rhinitis, non specific polyps, angioedema, urticaria or allergic reactions to aspirin or other nonsteroidal anti-inflammatory analgesics(including COX-2 inhibitors)
• Any other reason or situations that the investigator decides the patient is not eligible to participate the clinical trial.

None (open label)